ATE393235T1 - Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung - Google Patents

Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung

Info

Publication number
ATE393235T1
ATE393235T1 AT01997561T AT01997561T ATE393235T1 AT E393235 T1 ATE393235 T1 AT E393235T1 AT 01997561 T AT01997561 T AT 01997561T AT 01997561 T AT01997561 T AT 01997561T AT E393235 T1 ATE393235 T1 AT E393235T1
Authority
AT
Austria
Prior art keywords
fgf2
growth factor
fibroblast growth
vector encoding
paramyxovirus vector
Prior art date
Application number
AT01997561T
Other languages
English (en)
Inventor
Yoshikazu Yonemitsu
Katsuo Sueishi
Masayuki Fukumura
Xiaogang Hou
Mamoru Hasegawa
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of ATE393235T1 publication Critical patent/ATE393235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01997561T 2000-11-27 2001-11-27 Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung ATE393235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000359374 2000-11-27

Publications (1)

Publication Number Publication Date
ATE393235T1 true ATE393235T1 (de) 2008-05-15

Family

ID=18831146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01997561T ATE393235T1 (de) 2000-11-27 2001-11-27 Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung

Country Status (12)

Country Link
US (3) US20040005296A1 (de)
EP (1) EP1344829B1 (de)
JP (1) JP4212357B2 (de)
KR (1) KR100812884B1 (de)
CN (1) CN100357443C (de)
AT (1) ATE393235T1 (de)
AU (1) AU2002224113A1 (de)
CA (1) CA2430112C (de)
DE (1) DE60133767T2 (de)
DK (1) DK1344829T3 (de)
ES (1) ES2305138T3 (de)
WO (1) WO2002042481A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143892C (zh) * 1995-11-01 2004-03-31 株式会社载体研究所 重组仙台病毒
ES2326101T3 (es) * 1998-07-03 2009-09-30 Dnavec Research Inc. Vector de virus arn cadena (-) para celulas nerviosas.
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
DK1211318T3 (da) * 1999-09-06 2007-11-12 Dnavec Research Inc Paramyxovira omfattende en modificeret transkriptionsstartsekvens
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
EP1270016A4 (de) 2000-03-30 2005-10-19 Dnavec Research Inc Aidsvirus-impfstoff unter verwendung eines sendaivirus-vektors
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
EP1297852A4 (de) * 2000-06-27 2004-12-29 Dnavec Research Inc Viraler vektor zur einbringung von genen in nierenzellen(03.02.03)
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2002224113A1 (en) * 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
JPWO2003092738A1 (ja) * 2002-04-30 2005-09-08 株式会社ディナベック研究所 ヘマグルチニン活性を低下させた薬剤または遺伝子運搬組成物
AU2003261931A1 (en) * 2002-09-04 2004-03-29 Dnavec Research Inc. Process for producing virus vector containing membrane protein having sialic acid-binding activitiy in envelope with the use of gram-positive bacterium-origin neuraminidase
CA2503317A1 (en) * 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
EP1642966B1 (de) * 2003-06-30 2010-03-03 Dnavec Research Inc. Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
DE10333217A1 (de) * 2003-07-22 2005-03-10 Biomay Prod & Handel Polypeptide, hierfür kodierende Nucleinsäuren aus dem Schimmelpilz Cladosporium herbarum sowie deren Herstellung und Verwendung in Diagnostik und Therapie
EP1715048A4 (de) * 2004-01-22 2007-02-07 Dnavec Research Inc Verfahren zur herstellung eines virusvektors
CN1957084A (zh) * 2004-03-23 2007-05-02 株式会社载体研究所 与组织的维持和/或修复相关联的骨髓相关细胞
EP2993235B1 (de) 2005-10-28 2019-02-13 ID Pharma Co., Ltd. Gentransfer in epithelialen stammzellen der atemwege unter verwendung von similian lentiviralen vektoren mit senadai rna-virus-spikeprotein pseudotypisierten vektoren
KR101336386B1 (ko) * 2011-06-17 2013-12-04 전북대학교병원 림프관 생성 유도제
CA3176712A1 (en) 2013-03-15 2014-09-18 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejunevating human cells
MY187966A (en) * 2013-04-26 2021-11-02 Genomatica Inc Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US20160312261A1 (en) * 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
EP4110803A4 (de) * 2020-02-27 2024-03-27 Icahn School of Medicine at Mount Sinai Vegfr-3-aktivierende mittel und onkolytische viren und verwendungen davon zur behandlung von krebs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
GB8821795D0 (en) 1988-09-16 1988-10-19 Erba Carlo Spa New derivatives of human/bovine basic fibroplast growth factor
IT1237795B (it) * 1989-12-22 1993-06-17 Erba Carlo Spa Fattori di crescita fibroblastici per l'uso nella prevenzione e nel trattamento di infezioni virali.
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
CN1143892C (zh) * 1995-11-01 2004-03-31 株式会社载体研究所 重组仙台病毒
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
KR20070058607A (ko) 1999-05-18 2007-06-08 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
WO2000070055A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
WO2001032898A2 (en) 1999-11-02 2001-05-10 Dnavec Research Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
SE0000285D0 (sv) 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
CA2397903A1 (en) * 2000-01-19 2001-07-26 Dnavec Research Inc. Use of paramyxovirus vector for gene transfer into blood vessel
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
CN1526014A (zh) * 2000-10-06 2004-09-01 ��ʽ���������о��� 用于将外源基因导入骨骼肌的副粘病毒载体
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2002224113A1 (en) * 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
CN1957084A (zh) * 2004-03-23 2007-05-02 株式会社载体研究所 与组织的维持和/或修复相关联的骨髓相关细胞

Also Published As

Publication number Publication date
US20110212059A1 (en) 2011-09-01
KR20030074627A (ko) 2003-09-19
JP4212357B2 (ja) 2009-01-21
CN100357443C (zh) 2007-12-26
US20100158867A1 (en) 2010-06-24
JPWO2002042481A1 (ja) 2004-03-25
EP1344829B1 (de) 2008-04-23
ES2305138T3 (es) 2008-11-01
KR100812884B1 (ko) 2008-03-11
EP1344829A4 (de) 2005-01-05
WO2002042481A1 (fr) 2002-05-30
CA2430112A1 (en) 2003-05-27
US20040005296A1 (en) 2004-01-08
DE60133767T2 (de) 2009-06-25
US8211868B2 (en) 2012-07-03
DE60133767D1 (de) 2008-06-05
DK1344829T3 (da) 2008-09-01
CN1487999A (zh) 2004-04-07
AU2002224113A1 (en) 2002-06-03
CA2430112C (en) 2010-07-27
EP1344829A1 (de) 2003-09-17

Similar Documents

Publication Publication Date Title
ATE393235T1 (de) Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung
DE60133991D1 (de) Antisense inhibierung der ptp1b expression.
DK1019428T3 (da) Inverterede kimæriske og hybride oligonucleotider
EP1315830A4 (de) Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
DE69808614D1 (de) Stabilisationsschlinge zum gebrauch in der minimal-invasiven beckenchirurgie
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
BR0203172A (pt) Agentes terapêuticos para acondroplasia
MX2010003606A (es) Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
GB2365867B (en) Vector constructs
WO2000063246A3 (en) Compounds and methods for modulating beta-catenin mediated gene expression
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
BRPI0209824B8 (pt) método ex vivo ou in vitro para induzir cardiomiogênese
ATE363914T1 (de) Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
BR0209144A (pt) Composição associadas ao fator de crescimento de fibroblasto humano
IL194383A (en) Antisense oligonucleotide targeted to insulin-like growth binding protein 5
WO2002055659A3 (en) Antisense modulation of integrin beta 4 binding protein expression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1344829

Country of ref document: EP